Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 238

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 238
---
Management of Profusa — Executive and Director Compensation” for information regarding the compensation
of Profusa’s executive officers and directors.

Severance Arrangements

Profusa has entered into severance
arrangements with certain of its executive officers. For more information regarding these agreements, see the section titled “Management of Profusa — Executive and Director Compensation of Profusa — Additional Narrative Disclosure — Severance Arrangements.”

Indemnification Agreements

We entered into new indemnification
agreements with each of our directors and executive officers that are not already party to indemnification agreements. The indemnification
agreements, our amended and restated certificate of incorporation and our amended and restated bylaws require us to indemnify our directors
to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our amended and restated bylaws also require it
to advance expenses incurred by the combined company’s directors and officers.

<div align='center'>140</div>

NorthView Related Party Transactions Pre-Business Combination

Founder Shares

In April 2021, our sponsor
purchased 5,175,000 founder shares for an aggregate purchase price of $25,000. In October 2021, our sponsor forfeited 862,500 founder
shares. On December 20, 2021, we effected a 1.1-for-1 stock dividend of our common stock, resulting in an aggregate of 4,743,750
founder shares (up to 618,750 of which are subject to forfeiture).

Our sponsor purchased an aggregate
of 5,162,500 private placement warrants, each exercisable to purchase one share of common stock at $11.50 per share, at a price of $1.00
per warrant ($5,162,500 in the aggregate), in a private placement that closed simultaneously with the closing of our initial public offering.
The private placement warrants (including the shares of common stock issuable upon exercise of the private placement warrants) may not,
subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of our initial business
combination.

If any of our officers or directors
becomes aware of a business combination opportunity that falls within the line of business of any entity to which he or she has then-current fiduciary
or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior to presenting
such business combination opportunity to us. Our executive officers and directors currently have certain